

Technology Advisory Committee B Interests Register
Pegunigalsidase alfa for treating Fabry disease [ID3904]
Publication Date: 13/09/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Warren Linley	TAC B Committee Member	Direct – financial	Warren previously did some paid consulting with Amicus for Fabry disease about 2-3 years ago. Amicus is a comparator company.	21/06/2023	N/A	It was agreed that Warren's declaration would prevent him from participating in discussions on this appraisal.
Dr Sophie Thomas	Clinical Expert	Direct – non-financial	<p>PPV member of RDAG</p> <p>LSD Collaborative representative on the NHS national framework for the supply of home delivery services for LSD's</p> <p>LSD collaborative representative on transition planning peer review group</p> <p>LSD/ MPS patient group representative on NHSEI annual LSD clinical meeting</p>	15/11/2022	N/A	It was agreed that Sophie's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Veline L'Esperance	TAC B Committee Member	Direct	Veline is currently working on a Quality Improvement regarding Shingles vaccinations in primary care. This project will be funded by Sanofi.	29/06/2023	N/A	It was agreed that Veline's declaration would prevent him from participating in discussions on this appraisal.
Mariana Bacelar	TAC B Committee Member	Non-Financial Professional & Personal Interests	Part of the same EAG group (BMJ-TAG) that will be covering Peg alfa	06/07/2023	N/A	It was agreed that Mariana's declaration would prevent her from participating in discussions on this appraisal.
Professor Robin Lachman	Clinical Expert	Direct – financial	<p>Robin has received honoraria for speaking and travel expenses from Sanofi Genzyme.</p> <p>He has also received consulting fees from Sanofi Genzyme related to olipudase alfa for acid sphingomyelinase deficiency.</p> <p>Has received consulting fees from Biomarin related to their</p>	27/10/2022	N/A	It was agreed that Robin's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>gene therapy programme for phenylketonuria.</p> <p>He has received honoraria for speaking from Amicus.</p> <p>He has received consulting fees and honoraria for speaking from Takeda for work related to professional development programmes.</p>			